Saracatinib is Src inhibitor with IC50 of 2.7 nM.

PP2 is a ATP-competitive inhibitor of the Src family of protein tyrosine kinases. The IC50s for p56lck, p59fynT, Hck, Src are 4 nM, 5 nM, 5 nM, 100 nM, respectively.

PP1 is a selective inhibitor of Src and Lck/Fyn with IC50 of 5 nM, 6 nM, respectively.

WH-4-023 is an inhibitor of Lck and Src with IC50 of 2 nM, 6 nM, respectively.

CCT196969 is active against melanoma and colorectal cancer cell lines that are mutant for BRAF, but not cancer cells that are wild-type for BRAF and NRAS. CCT196969 induces caspase 3 and PARP cleavage, thus induces apoptosis. CCT196969 does not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma.